Brilinta Tablet
Product Images NDC 0186-0776

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Brilinta (NDC 0186-0776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 mg Label

BRILINTA 60 mg oral tablet label showing the product name, active ingredient ticagrelor, dosage strength of 60 mg, and quantity of 60 tablets. The label includes the AstraZeneca Pharmaceuticals LP brander information and notes the prescription-only status along with a reminder to dispense a Medication Guide with the product.*

FDA Label Image

90 mg Label

BRILINTA 90 mg ticagrelor tablets label for oral use, containing 60 tablets. The packaging shows the AstraZeneca Pharmaceuticals LP labeler information, with the NDC 0186-0777-60. The label advises that it is prescription only and includes a notice to dispense the accompanying Medication Guide with each patient.*

FDA Label Image

Figure 1

A Kaplan-Meier cumulative event curve comparing Ticagrelor 90 mg versus Clopidogrel over 360 days from first study drug dose. The y-axis shows cumulative percentage of events, and the x-axis shows days from dose. The graph includes patient counts at risk at various time points for both treatments.*

FDA Label Image

Figure 2

A bar chart showing the percentage of patients who had an event following CABG (Coronary Artery Bypass Grafting) over a period of days. The x-axis represents days (1 through >=8), and the y-axis shows the percentage of patients having events, ranging from 0 to 100. Two groups, labeled T and C, are compared with distinct bars for each day. A table below the chart presents numerical patient event counts corresponding to T and C groups for each day.*

FDA Label Image

Chemical Structure

Chemical structure of Ticagrelor, the active ingredient in BRILINTA oral tablets, showing the molecular arrangement of atoms including fluorine, sulfur, nitrogen, oxygen, and carbon used in the compound.*

FDA Label Image

Figure 08

A figure titled 'Mean effect and 90% CI' showing the pharmacokinetic impact of various interacting drugs on Ticagrelor. The graph plots changes in Cmax and AUC relative to reference values for drugs including strong and moderate CYP3A4 inhibitors, CYP3A4 inducers, and others, alongside dosing recommendations such as dose adjustments or avoidance of concomitant use.*

FDA Label Image

Figure 10

A Kaplan-Meier curve showing cumulative percentage of patients with events over 360 days from randomization comparing BRILINTA (ticagrelor) 90 mg versus clopidogrel. The graph includes number of patients at risk at different time points and statistical data such as hazard ratio, confidence interval, and p-value.*

FDA Label Image

Figure 11

A forest plot comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across various patient characteristics and treatment subgroups. It displays event counts and percentages per year for both drugs, illustrating treatment effects in geographic regions, ASA dosage, planned treatment approach, early PCI, CABG status, diabetes history, prior TIA/stroke, glycoprotein inhibitor use, age groups, sex, and race. Ticagrelor is shown on the left (HR <1) and Clopidogrel on the right (HR >1).*

FDA Label Image

Figure 12

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across different aspirin (ASA) dose ranges in US and Non-US regions. The graph visually represents effectiveness, indicating whether Ticagrelor or Clopidogrel is favored based on HR values for various ASA dose categories.*

FDA Label Image

Figure 13

A cumulative percentage line graph showing patient event rates over 1320 days from randomization comparing Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo. The graph includes event data, hazard ratios, confidence intervals, and p-values in a legend box, along with patient counts at risk for each group at various time points.*

FDA Label Image

Figure 14

A forest plot chart showing the overall treatment effect of Ticagrelor versus placebo across multiple patient subgroups. The variables include age groups, sex, race, weight, BMI, geographic region, history and time from myocardial infarction, diabetes status, coronary artery disease, kidney function, type of stent, smoking status, and prior ADP receptor blocker treatment. The chart displays hazard ratios with 95% confidence intervals comparing Ticagrelor and placebo outcomes.*

FDA Label Image

Figure 15

A line graph comparing the cumulative percentage (%) of events over time in months from randomization between Ticagrelor and placebo groups. The graph shows two lines: a solid line for Ticagrelor and a dashed line for placebo, with cumulative percentages on the y-axis and time in months on the x-axis up to 54 months. A risk table below indicates the number of patients at risk for each group over time.*

FDA Label Image

Figure 16

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics between Ticagrelor and placebo groups. The plot includes subgroups by age, sex, race, body mass index, geographic region, aspirin dose, HbA1c levels, kidney function, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and diabetes duration. The x-axis indicates treatment effect with Ticagrelor better on the left and placebo better on the right.*

FDA Label Image

Figure 17

A Kaplan-Meier curve showing cumulative percentage over time (days from randomization) comparing Ticagrelor 90 mg twice daily versus placebo. The graph includes event counts and cumulative percentages for each group and displays numbers at risk over a 34-day period.*

FDA Label Image

Figure 18

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals (CI) for the effectiveness of Ticagrelor versus placebo across various patient subgroups. The plot includes characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis, time from event to treatment, comorbidities, prior treatments, and smoking status, showing outcome percentages and HR values for each subgroup.*

FDA Label Image

Figure 3

A line graph showing cumulative percentage over months from randomization for Ticagrelor and Placebo groups. The x-axis represents time in months up to 54, and the y-axis shows cumulative percentage. Two lines depict Ticagrelor (solid) and Placebo (dashed) event rates, with accompanying risk population numbers below the x-axis and an events/N legend at the top left.*

FDA Label Image

Figure 4

A Kaplan-Meier cumulative percentage curve graph comparing Ticagrelor 90 mg twice daily (solid line) and placebo (dashed line) over 30 days from randomization. The graph shows cumulative percentage on the y-axis and days on the x-axis, with risk population counts listed below the x-axis. Ticagrelor shows a higher event cumulative percentage compared to placebo.*

FDA Label Image

Figure 5

A line graph comparing IPA percentage induced by 20µM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The graph shows Ticagrelor reaching about 90% IPA quickly and maintaining it, Clopidogrel rising to about 50% IPA more gradually, and placebo remaining near zero with a slight increase.*

FDA Label Image

Figure 6

A line graph showing the percent inhibition of platelet aggregation (IPA %) induced by 20 µM ADP over a 10-day period for Ticagrelor, Clopidogrel, and Placebo groups. The graph includes a smaller inset depicting the same measurement over 48 hours. Ticagrelor is represented with circles, Clopidogrel with triangles, and Placebo with squares, illustrating changes in IPA over time.*

FDA Label Image

Figure 7

A forest plot chart showing mean effect and 90% confidence intervals (CI) for ticagrelor and its metabolite AR-C124910XX across intrinsic factors such as age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment. The chart compares Cmax and AUC parameters with a recommendation of no dose adjustment for each factor. Data points include confidence intervals relative to reference values.*

FDA Label Image

Image 09

A chart showing the mean effect and 90% confidence intervals of various interacting drugs when used with Ticagrelor at different doses. The chart compares changes relative to the interacting drug alone for simvastatin, atorvastatin, lewonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine. Recommendations on dose adjustments are given, including a maximum simvastatin dose of 40 mg and monitoring digoxin levels when starting or changing BRILINTA therapy.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.